XML 44 R7.htm IDEA: XBRL DOCUMENT v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating activities:    
Net loss $ (57,591,000) $ (20,588,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Credit loss - related party accounts receivable 0 117,000
Stock-based compensation expense 3,948,000 439,000
Non-cash lease expense 380,000 235,000
Unrealized loss on short-term investments 5,000 217,000
Amortization of discount on short-term investments (1,306,000) (96,000)
Depreciation expense 36,000 16,000
Changes in operating assets and liabilities:    
Prepaid expenses and other assets (5,960,000) (412,000)
Accounts payable 239,000 798,000
Accrued liabilities 6,415,000 1,385,000
Operating lease liability (338,000) (198,000)
Net cash used in operating activities (54,172,000) (18,087,000)
Investing activities:    
Purchases of short-term investments (129,599,000) (11,889,000)
Maturities/sales of short-term investments 80,027,000 0
Purchases of property and equipment (95,000) (109,000)
Net cash used in investing activities (49,667,000) (11,998,000)
Financing activities:    
Proceeds from sale and issuance of common stock in initial public offering, net of underwriting discounts 91,075,000 0
Financing costs paid in connection with initial public offering (2,387,000) 0
Proceeds from sale and issuance of Series C convertible preferred stock 0 85,000,000
Financing costs paid in connection with issuance of Series C convertible preferred stock 0 (2,148,000)
Proceeds from exercises of common stock options 366,000 332,000
Proceeds from issuance of common stock under employee stock purchase plan 195,000 0
Costs paid in connection with deferred financing costs 0 (1,193,000)
Net cash provided by financing activities 89,249,000 81,991,000
Net (decrease) increase in cash and cash equivalents (14,590,000) 51,906,000
Cash and cash equivalents at beginning of year 61,641,000 9,735,000
Cash and cash equivalents at end of year 47,051,000 61,641,000
Supplemental Cash Flow Information [Abstract]    
Operating right-of-use assets in exchange for operating lease liability 0 815,000
Early exercise options and unvested stock liability 26,000 8,000
Deferred financing costs included in accounts payable and accrued expenses 0 1,136,000
Conversion of convertible preferred stock into common stock upon initial public offering $ 126,756,000 $ 0